biotherapeutics

Discover the benefits of VHH antibody-based therapies.

In this webinar, Patrick Schmidt will explore how to streamline CAR T cell product manufacturing processes for immunotherapy. 

Discover tips for guiding drug development from discovery to the clinic.

Translational research and drug discovery meet at the intersection of novel multiomics technologies.

Electron activated dissociation (EAD) and the Zeno trap provide high sensitivity and certainty in mass spectrometry results.

Electron activated dissociation (EAD) and the Zeno trap provide high sensitivity and certainty in mass spectrometry results. 

Launched with a $172 million philanthropic donation and funds from the state of Victoria, the Melbourne-based research institute aims to construct drug discovery platforms to speed the introduction of new therapies.

Explore the future of biopharma research and development.

The Scientist Social Club sat down with the author.

Immunologists and parasitologists are working to revive the idea that helminths, and more specifically the molecules they secrete, could help treat allergies and autoimmune disease.

RNA editing has been in DNA editing’s shadow for nearly a decade, but recent investments in the technology could bring it into the limelight.

RNA editing platforms leverage the natural activity of ADAR enzymes to make key changes to messenger RNAs before they are translated into proteins.

Targeted, genome-wide CRISPR editing in yeast improves protein yield.

Experts will discuss potential neutralizing antibodies currently under investigation for SARS-CoV-2 treatment.

Lonza will employ more than 200 full-time staff to work at the Texas-based facility, the company says.

The biotech firm Celgene inks a huge collaboration deal with Juno Therapeutics to develop and commercialize new cancer immunotherapies.

With one US patent awarded and many other applications under consideration for the popular genome-editing technology, companies are adopting multiple strategies to navigate the complex intellectual property landscape.

Tumor-targeting T-cell therapies are generating remarkable remissions in hard-to-beat cancers—and attracting millions of dollars of investment along the way.

Now showing clinical progress against liver diseases, the gene-silencing technique begins to fulfill some of its promises.